Endothelial-to-mesenchymal transition in pulmonary hypertension. - Wikidata - wikimedia - TriplyDB

Endothelial-to-mesenchymal transition in pulmonary hypertension.

Endothelial-to-mesenchymal transition in pulmonary hypertension.

http://www.wikidata.org/entity/Q55068646

about

Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases Endothelial-Mesenchymal Transition in Regenerative Medicine Endothelial Plasticity: Shifting Phenotypes through Force Feedback BMPR2 spruces up the endothelium in pulmonary hypertension DNA Damage and Pulmonary Hypertension Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Fine-tuning vascular fate during endothelial-mesenchymal transition.RUNX3 modulates hypoxia-induced endothelial-to-mesenchymal transition of human cardiac microvascular endothelial cells.Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.To be EndMT or not to be, that is the question in pulmonary hypertension Integrin β3 inhibition is a therapeutic strategy for supravalvular aortic stenosis.Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1.Serine Protease Activation Essential for Endothelial-Mesenchymal Transition in Vascular Calcification.Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis.Endothelial-Mesenchymal Transition in Vascular Calcification of Ins2Akita/+ Mice.Monocrotaline Induces Endothelial Injury and Pulmonary Hypertension by Targeting the Extracellular Calcium-Sensing Receptor.Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.Reversibility of Stricturing Crohn's Disease-Fact or Fiction?Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension Update in Pulmonary Vascular Disease 2015.Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series).Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.Pigment epithelium-derived factor attenuates myocardial fibrosis via inhibiting Endothelial-to-Mesenchymal Transition in rats with acute myocardial infarction.miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.Molecular pathogenesis and current pathology of pulmonary hypertension.Macrophage-derived foam cells impair endothelial barrier function by inducing endothelial-mesenchymal transition via CCL-4.Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease.Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.

P2860

Q26748338-7A2A525D-7ECE-4AE6-8617-A6068679112F Q26752901-78964DDF-437D-43D2-B91F-DA64797B0EE5 Q26767430-CBB031E4-73D5-4C8E-8A97-8E1911C1F58F Q26786834-8D6CA2A8-0A81-4715-A6B8-BFDABD01307B Q27005594-A60DC3BA-454A-4418-892F-8E9118C220FB Q27313607-EFE5A436-242D-45E0-87EB-73BC6206B294 Q28067063-A91364B2-5EE2-434E-86F2-1C7D3CF02723 Q30275793-216F1B2E-6B47-4850-A744-F20C2554375F Q33783985-FB277C30-309D-4059-950A-55648C20E0F9 Q35770782-C7ABA89A-DB02-4C0A-9E4E-663014442EBD Q35796190-56A7ED56-3825-4AA8-988C-94ABCAD78990 Q35862861-EC78C217-B004-4D2A-8E85-A519F80F266D Q35917857-BF5B22EB-F47F-4A9E-AE30-04E774CD868B Q36119874-1D0A8BF7-9F61-46D1-A8FF-0BA01856B4F3 Q36144932-66C4A7B7-44FE-4EAB-8D7B-3A40D55F7373 Q36145584-3EC5CDAB-8119-417E-8B12-70D0A74F1177 Q36218686-E2E95F19-5F87-483B-A55E-F24602A6188D Q36318985-B00F5055-3BDE-4223-9756-285457F22F6E Q36352101-499AFA71-680B-4B91-81BA-7F020ABB3708 Q36373253-FC4C8B07-BAFD-4261-B213-4B9E143F57BC Q36769101-1BC3F142-A443-4ECE-A3BC-2A739D361B08 Q36817403-C90375D0-B503-4392-A722-A400DF4500E0 Q36869381-2884E84D-9F3B-4029-A640-B426A7585BE3 Q36996364-73D7C9B4-3E71-463D-810C-0C3A14381755 Q37013164-CF584E13-95C9-4D85-A010-8C80B4E999CE Q37217460-601ECE8E-4939-4086-8515-7B34A420A0DE Q37316247-C0C03C2F-0EA2-4DCE-A02E-13DAE5A0822B Q37555431-74021A24-D641-47C5-BB6C-37319341CB4B Q37555457-0390F749-B0D2-4E5C-968F-8EC3EACD0CFF Q37555854-F55D09D8-8CC9-4480-B299-48F713B0A2E6 Q37627860-70FC6048-1261-4B9A-B4A7-513BB9CED456 Q38383813-41B99AA0-02D6-48FD-A3A5-75A4C98A79E4 Q38676413-77E73E9A-BA2F-468A-A845-95F500EE9E4A Q38705951-F2932138-CB07-4E0F-A468-B730786111DD Q38710580-FD3B1B63-F675-45D0-8B56-14F83C31EA07 Q38732718-2D609144-2A69-4180-B080-D0A6FAD82628 Q38736112-E33154D2-6432-46EF-BC51-E106578FE7D5 Q38779774-9672F2C4-33A5-4877-B419-AB9F5C9CE90C Q38817806-1B255B6C-380C-4E45-BDE4-68F4CD5FD611 Q39010196-FED6A7BF-1CD8-40D4-9124-0B431A50941E

P2860

Endothelial-to-mesenchymal transition in pulmonary hypertension.

http://www.wikidata.org/entity/Q55068646

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@en

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@nl

type

label

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@en

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@nl

prefLabel

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@en

Endothelial-to-mesenchymal transition in pulmonary hypertension.

@nl

P1433

Q55068646-0FE75F9E-8511-4963-AE21-86DAC66A47C8

P1476

Q55068646-4496EC70-E1F8-442A-AE08-366B00DE31DD

P2093

Q55068646-189B862C-A583-420B-BC7F-2DFF89D54EBD

Q55068646-1E701999-EC05-4150-8F2B-BD3505235746

Q55068646-2DF63544-37A3-450D-8BEA-C65395F819DA

Q55068646-7321199F-ECAE-4B62-83F6-96D08AEA199F

Q55068646-79165D77-8BA5-4CCE-AC6B-11D16114991C

Q55068646-9B171F8A-2638-4539-87F8-BD8B1C2456C5

Q55068646-9EC6ABCA-E95F-49C2-B866-5B3A4EBF941E

Q55068646-A32C30E2-2A38-49A3-961A-6B035776819E

Q55068646-AC5ACBEA-DC29-4711-AD1D-294ABD8F059D

Q55068646-B56B2040-581A-4CFF-8EC7-D3DF128A43BC

P304

Q55068646-D8A3299A-EFFC-4721-9966-CA053FC45FBF

P31

Q55068646-20038F28-6399-40CB-8B46-5A3C4552CBEE

P356

Q55068646-565B1D12-93FB-4813-A198-5C3E1C160F28

P407

Q55068646-C1ABA0B7-6829-4C7C-AF14-C05474E54361

P433

Q55068646-36D0B61A-6005-426C-84D0-9AB0F2E725A4

P478

Q55068646-45B748F0-D5B1-4225-B350-BBF659CDCD69

P50

Q55068646-0AAA981B-135A-440E-A4E0-7CE15E1E1A48

Q55068646-11073980-BB86-4606-990B-595A17862F49

Q55068646-30420447-5ECB-4B03-85DA-18F2993A3B67

Q55068646-3B6CFB4B-9CC4-49FA-AF6E-72CFC29CFB61

Q55068646-4281C220-96DE-42B8-9ED5-73132777809A

Q55068646-D393C2DB-1045-4292-BA97-3EAAC74274C6

P577

Q55068646-D7C87A6E-DDDC-4349-A71D-B4FDDCD628B5

P5875

Q55068646-54129A76-8458-49FA-9A62-3519774FA663

P698

Q55068646-68189B88-1017-4454-A073-75FD18F218DF

P921

Q55068646-105F534F-893D-475B-BF46-7C0D121C3083

P356

CIRCULATIONAHA.114.008750

P1433

P1476

Endothelial-to-mesenchymal transition in pulmonary hypertension

@en

P2093

Amal Houssaini

http://www.w3.org/2001/XMLSchema#string

Aurélie Hautefort

http://www.w3.org/2001/XMLSchema#string

Christine Péchoux

http://www.w3.org/2001/XMLSchema#string

Elie Fadel

http://www.w3.org/2001/XMLSchema#string

Florence Lecerf

http://www.w3.org/2001/XMLSchema#string

Gerald Simonneau

http://www.w3.org/2001/XMLSchema#string

Harm Jan Bogaard

http://www.w3.org/2001/XMLSchema#string

Ignacio Anegon

http://www.w3.org/2001/XMLSchema#string

Serge Adnot

http://www.w3.org/2001/XMLSchema#string

Sophie Chat

http://www.w3.org/2001/XMLSchema#string

P304

1006-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.114.008750

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Peter Dorfmuller

Frédéric Perros

Fabrice Antigny

Catherine Rucker-Martin

Benoit Ranchoux

P577

2015-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270907450

http://www.w3.org/2001/XMLSchema#string

P698

25593290

http://www.w3.org/2001/XMLSchema#string

P921